Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00809354 · ClinicalTrials.gov registry record · Phase 3
Long-Term Analgesic Efficacy And Safety Of Tanezumab Alone Or In Combination With Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Versus NSAIDs Alone In Patients With Osteoarthritis Of The Knee Or Hip
A Phase 3 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 3
- Development phase
- 2,720
- Enrollment target
NCT00809354: Clinical Trial Phase 3 study, sponsored by Pfizer.
NCT00809354 is a Phase 3 study that was terminated before completion, run by Pfizer. The registered enrollment target is 2,720 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (252% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00809354, a Phase 3 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 2,720 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the long-term analgesic efficacy and safety of tanezumab for patients with osteoarthritis (OA) of the knee or hip currently experiencing partial benefit from, and are tolerating, non-steroidal anti-inflammatory drug (NSAID) therapy.
Primary Outcome
WOMAC: self-administered, disease-specific 24-item questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis of index joint (knee or hip). The WOMAC pain subscale was a 5-item questionnaire used to assess the amount of pain experienced due to osteoarthritis of index joint (knee or hip) during past 48 hours. It was calculated as mean of the scores from 5 individual questions scored on a numerical
Interventions
- DRUG NSAID
- BIOLOGICAL tanezumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,720 participants |
| Start Date | 2009-02-12 |
| Est. Completion | 2011-01-12 |
| Phase | Phase 3 |
Why NCT00809354 stopped before completion
NCT00809354 is an interventional study that assigns participants to a tested intervention. Its 2,720 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (252% higher).
The record links to 0 conditions, and to 2 interventions - of which NSAID is the first listed.
NCT00809354 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00809354 about?
NCT00809354 is a clinical study titled "Long-Term Analgesic Efficacy And Safety Of Tanezumab Alone Or In Combination With Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Versus NSAIDs Alone In Patients With Osteoarthritis Of The Knee Or Hip". The purpose of this study is to investigate the long-term analgesic efficacy and safety of tanezumab for patients with osteoarthritis (OA) of the knee or hip currently experiencing partial benefit from, and are tolerating, non-steroidal anti-inflammatory drug (NSAID) therapy.
What is the current status of trial NCT00809354?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 2,720 participants. The study started on 2009-02-12. Estimated completion is 2011-01-12.
What interventions are being tested in trial NCT00809354?
The interventions under investigation include: NSAID (DRUG), tanezumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00809354?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00809354's enrollment target sits among peer trials
2,720 83rd of 2000 higher than 1,918 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06085833 · 2,706 participants · NA
ARTIDIS Nanomechanical Generated Measurements for Early Breast Lesions
- NCT04073420 · 2,700 participants
Medtronic Cardiac Surgery PMCF Registry
- NCT05125939 · 2,700 participants
Can Overall Adenoma Detection Rate Replace Screening Adenoma Detection Rate ? Multicenter Study
- NCT05586776 · 2,700 participants · Phase 4
Decolonization to Reduce After-Surgery Events of Surgical Site Infection
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI